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clinical outcomes and medical resource utilization (MRU)
derived from the phase III ML17032 study. Direct medical costs
associated with trial-based MRU were based on Taiwan’s
National Health Insurance fee schedule for 2007. Costs associ-
ated with intravenous chemotherapy administration and adverse
event (AE) management were estimated by an expert panel
survey conducted among 12 oncologists. One-way sensitivity
analyses were performed on key model parameters by varying the
input values by 20%. RESULTS: A trend toward superior
progression-free survival was observed in the XP arm (median
5.6 months for XP vs. 5.0 for FP). Patients in the XP arm received
5.2 cycles of therapy vs. 4.6 cycles of FP. Compared to FP,
administration of XP required fewer consults per patient (5.2
for XP vs. 22.8 for FP). Chemotherapy drug cost was higher
(USD$1712) in the XP arm; however, these cost increments
were offset by differences of chemotherapy administration costs
(USD$4376) between two arms. AE proﬁles were similar and the
cost associated with grade 3/4 AE management were slightly
lower (USD $30) in the XP arm. Overall, XP was associated
with a cost saving of USD$2691(NTD$87,351). XP remained
cost-saving under one-way sensitivity analyses. CONCLUSION:
From the Taiwan BNHI perspective, this CMA demonstrates that
replacing FP by XP for the treatment of AGC would not only
save direct medical costs but also improve health outcomes in
Taiwan.
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OBJECTIVE: To undertake a cost-consequence analysis of
direct medical costs in the treatment of advanced oesophago-
gastric cancer based on the REAL 2 randomized clinical trial,
which demonstrated non-inferiority when oral capecitabine was
substituted for infusional 5FU as part of the standard regimen,
ECF. METHODS: Direct medical costs (2007 CDN$) from the
perspective of the Canadian public health system were applied
to resources (e.g., study treatment, toxicity management)
obtained from REAL 2 trial data available in the public
domain. Complete drug delivery was assumed. Mean overall
costs per patient were estimated over six cycles, corresponding
to treatment duration. RESULTS: The mean total cost per
patient treated with ECF was $9065 and $9268 for ECX. The
major driver of cost in the ECX arm is chemotherapy drug,
$5472 for capecitabine versus $2400 for infusional 5FU (6
cycles). This is offset by the cost of chemotherapy administra-
tion, $1551 for ECF compared to $671 for ECX, and central
venous access costs, $1230 for ECF. Additional line complica-
tion and hospitalization data were not available and therefore
not included in these estimates. Limited data on toxicity man-
agement, (e.g. febrile neutropenia, anemia, thromboembolism),
are available, and cost estimates are $2955 for ECF
and $2433 for ECX-treated patients. CONCLUSION: ECX has
similar efﬁcacy to ECF in the REAL 2 trial, but has potential
advantages in terms of patient preference and convenience of
an oral therapy. In addition, oral therapy decreases hospital
resource consumption. While drug costs for ECX are greater,
costs for chemotherapy administration and line-related costs
are substantially less, and underestimated in this analysis. Sub-
stituting capecitabine for infusional 5FU in the ECF regimen is
an attractive and affordable alternative for patients with
advanced oesophagogastic cancer.
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OBJECTIVE: In Finland, the overall costs of breast cancer man-
agement have increased, primarily during the last years by the
launch of expensive pharmaceutical therapies (trastuzumab in
2000). Economical reasons may therefore play a part in the
prescribing of new drugs. We analyzed with comprehensive time
series of all expenditures the effectiveness of pharmaceutical
developments and other interventions from 1987 to 2005.
METHODS: Finnish registry based data from 1987 to 2005 was
combined to evaluate all costs related to the care of breast cancer.
These included comprehensive health care costs, sick-leave
compensations, disability pensions, and loss of productivity;
all converted to 2004 euros. Several scenarios were thereafter
constructed to identify the important changes in care processes
and cost drivers during this period. RESULTS: During the obser-
vation period, the number of patients with breast cancer (5-year
survival prevalence) increased by 100% up to 17,000 patients
and the overall expenditure of care more than doubled from €70
to €160 million. The health care costs increased by 150% and the
cumulative costs per patient increased from €4500 to €5500. The
cost of medications has escalated with an overall increase of
660%, mostly during 2000’s. However, during this period, the
effectiveness of the treatment has increased as breast cancer
related deaths, in-hospital days and loss of productivity due to
premature deaths have decreased signiﬁcantly. Altogether, our
scenarios showed that new medications have had a beneﬁcial
ﬁnancial impact of 16–35 million € for the society during the
study period. CONCLUSION: Comprehensive assessment of
large patient cohorts and long term economical outcomes is a
useful method for evaluation of outcomes in chronic diseases.
Identiﬁcation of different cost drivers is needed as the cost of new
interventions is increasing and their beneﬁts should ideally be
assessed in relation to their broader societal inﬂuence.
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OBJECTIVE: This study provides updated, in-depth estimates of
colorectal cancer (CRC) treatment costs. METHODS: This ret-
rospective cohort study included patients aged 65 years, who
were recently diagnosed with colon (CC) or rectal (RC) cancer in
a SEER registry between 1996 and 2002 (n = 60,916) and 1:1
matched (by age, sex, geographic region) non-cancer comparison
patients from a 5% Medicare sample. We assigned costs to
phases as follows: 1) initial: costs in the period up to one year
after diagnosis among patients with 13 months survival; 2)
continuing: costs in the years between the initial and terminal
years among patients with36 months survival; and 3) terminal:
costs in the ﬁnal year of life. Terminal costs were assigned ﬁrst
(all costs considered terminal for patients who lived <13
months). Costs reﬂect all provider payments for cancer patients
in excess of those for matched comparison patients (2006 US
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